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Objectives: Pertussis is endemic in the US despite recommendations for rou-
tine vaccination. Recent evidence suggests waning immunity among adolescents 
is one catalyst for the spread of disease. Although 89% of adolescents received 
Td/Tdap vaccine in 2012, little is known about coverage of pertussis containing 
vaccination specifically, or if Tdap is administered at age-appropriate times (age 
10 to 12 years). We sought to evaluate coverage and age-appropriate Tdap receipt 
among adolescents in the US. MethOds: Participant reported demographics and 
immunization provider reported vaccinations were analyzed from the 2010 and 
2011 National Immunization Survey-Teen. Among children aged 13 to 17 years, we 
assessed the proportion who received at least one dose of Tdap (coverage) and the 
age at administration (age-appropriate receipt). Among those who received Tdap, 
we estimated multivariable logistic regression models to identify factors associated 
with age-appropriate vaccination. Results: Between 2010 and 2011, the propor-
tion of adolescents who received at least one Tdap vaccination between the ages 
of 10 to 17 increased from 64.3% to 73.8%, respectively (p< 0.0001). Among those 
who received Tdap, 61.6% in 2010 to 71.3% in 2011 received age-appropriate vac-
cination (p< 0.0001). Among those who delayed Tdap vaccination, the mean age of 
vaccination was approximately 14 years in both 2010 and 2011. Among adolescents 
who received Tdap, having a mother with more than 12 years of education (OR= 1.2, 
p< 0.0001) increased the likelihood of age-appropriate vaccination. Whereas, not 
having an adolescent well-child visit (OR= 0.46, p< 0.0001), having multiple vacci-
nation providers (OR= 0.85, p< 0.0001), and having a gap in health insurance cover-
age (OR= 0.72, p= 0.0004) significantly decreased the likelihood of age-appropriate 
vaccination. cOnclusiOns: Coverage and age-appropriate receipt of Tdap among 
adolescents is suboptimal, yet improving. Overall, two-thirds of adolescents received 
Tdap, of which 29% to 38% received it after the recommended age, on average leaving 
two years during which pertussis immunity may have waned.
PIN78
PersIsTeNce oN aNTIreTroVIral TheraPy IN WomeN eNrolled IN The 
WIhs cohorT: 1998-2013
Hardy H.1, Rosenblatt L.1, Shi Q.2, Hoover D.R.3, Young M.4, Golub E.5, Greenblatt R.6, 
Augenbraun M.7, Burian P.8, Anastos K.9
1Bristol Myers Squibb, Plainsboro, NJ, USA, 2New York Medical College, Valhalla, NY, USA, 
3Rutgers, the State University of New Jersey, Piscataway, NJ, USA, 4Georgetown University 
Medical Center, Washington, DC, DC, USA, 5Johns Hopkins Bloomberg School of Public Health, 
Baltimore, MD, USA, 6University of California, San Francisco, San Francisco, CA, USA, 7SUNY 
Downstate Medical Center, Brooklyn, NY, USA, 8LAC-USC Medical Center, Los Angeles, CA, 9Albert 
Einstein College of Medicine and Montefiore Medical Center, Bronx, NY
Objectives: To assess persistence on protease inhibitors [PI; atazanavir/ritonavir 
(ATV±r), lopinavir/r (LPV/r), darunavir/r (DRV/r)]- or efavirenz (EFV)-based antiretro-
viral therapy (ART)] in the Women’s Interagency HIV Study (WIHS), a large, US, obser-
vational cohort. MethOds: This retrospective analysis of WIHS used bi-annually 
collected data from January 1998-April 2013. HIV+ women initiating ATV±r, LPV/r, 
DRV/r or EFV were followed until discontinuation of the index PI or EFV, dropout 
from cohort, or end of study period. Persistence on ATV±r, LPV/r, DRV/r or EFV over 
50 months stratified by prior ART experience (ART naive, 0-1 prior PI, ≥ 2 prior PIs) 
was analyzed using Kaplan-Meier curves. In the analysis, we considered patient 
baseline variables (demographics, co-morbidities, viral load, CD4, and depression/ 
quality of life and ART regimens used prior to initiating the index PI or EFV), and 
follow-up variables (adherence, reasons for ART discontinuation). Results: In total, 
661 women initiated ATV±r, 546 LPV/r, 203 DRV/r and 815 EFV-based regimens. Mean 
age was 41 years, > 50% were Black, > 15% were HCV+ and > 50% had prior illicit drug 
use. For women with no prior ART, persistence at 50 months was 54% for EFV, 53% 
for ATV±r, and 14% for LPV/r (P = 0.0015); DRV/r had unreliable data in ART-naïve 
due to small sample size). For ART exposed women with 0-1 PI, persistence was 64% 
for DRV/r, 50% for ATV±r, 49% for EFV, and 29% for LPV/r (P < 0.0001). For women 
with ≥ 2 prior PI exposure, persistence was 70% for DRV/r, 41% for ATV±r, 28% for 
LPV/r, and 23% for EFV (P < 0.0001). cOnclusiOns: Persistence differed among the 
ART regimens in analyses that stratified by prior ART/PI experience. Proportional 
hazards regression will be used to examine if case-mix differences contribute to 
these patterns.
PIN79
real-World PersIsTeNce WITh sINgle Versus mulTIPle TableT 
regImeNs For hIV-1 TreaTmeNT
Sweet D.E.1, Kim Y.2, Song J.3, Zhong Y.3, Signorovitch J.3
1The University of Kansas School of Medicine – Wichita, Wichita, KS, USA, 2Gilead Sciences, Inc., 
Foster City, CA, USA, 3Analysis Group, Inc., Boston, MA, USA
Objectives: Non-persistent use of any component of an antiretroviral (ARV) regi-
men can lead to viral replication and treatment resistance. We compared real-
world persistence between HIV-1 infected patients receiving once-daily single 
tablet regimens (STRs) versus multiple-tablet regimens (MTRs) using 7-year his-
tory in a claims database. In addition, we assessed whether initial MTR persis-
tence predicted long-term persistence comparable to an STR. MethOds: HIV-1 
infected patients filling ARV prescriptions after a 90-day washout were identified 
in a large claims database (07/2006-03/2013). Index regimens were classified as 
STRs (1 pill daily) or MTRs (≥ 2 pills daily). Persistence was measured as the time 
from starting the index regimen to the first 90-day prescription gap for any ARV 
in the index regimen, or to the first prescription for an ARV not in the index 
regimen. Persistence was compared between STRs and MTRs with a logrank test. 
Additionally, the subgroup persistent on MTRs for the first 6 months was compared 
to the full group receiving STRs and the subgroup persistent on STRs for the first 6 
months. Results: Among 3,590 patients who initiated ART, 1,909 (53%) patients 
Objectives: The study investigated the longitudinal effect of pharmacy manage-
ment programs on adherence rates for patients using dual therapy for the hepatitis 
C virus (HCV) within retail and central pharmacy channels. MethOds: This was a 
retrospective study of patients new to HCV therapy, who used either retail or central 
pharmacy channels to obtain their HCV prescriptions. Although the two channels 
had different operational structures, they provided similar patient management ser-
vices. The adherence metric was the proportion of days covered (PDC), as endorsed 
by the Pharmacy Quality Alliance. Active involvement with a patient management 
program for at least 90 days was examined as a predictor for adherence. Due to the 
different managed therapy models across channels, propensity scores were used 
to match patients for the retail analysis, and analysis of covariance was used for 
the central analysis. Results: Mean PDC rates for the retail patients improved 
significantly (16.2%, p < 0.0001) for patients managed at least 90 days compared to 
those less managed. Similarly, patients managed at least 90 days within the central 
distribution channel had significantly higher adherence rates (29.4%, p < 0.0001) 
than those who did not remain managed. Among retail patients managed at least 
90 days, the mean adherence level (77.9%) was comparable (i.e., not significantly 
different) to that of the central patients (76.8%). The proportion of patients who 
were adherent to medications (PDC ≥ 80%) indicated similar significant trends as 
for mean PDC. cOnclusiOns: Pharmacy services increased adherence to HCV dual 
therapy medications in both central and retail pharmacy channels, and reduced the 
difference in adherence between channels. Previous research has linked medica-
tion adherence to reduced viral loads from drug therapy, and improved clinical 
outcomes. Providing HCV pharmacy management programs that address patient 
adherence to therapy will likely improve the long-term health outcomes for these 
patients.
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bAckgROund: Compliance with HIV treatment guidelines has not been studied in 
a large sample of real-world patients. Objectives: Document the impact of guide-
lines and patient characteristics on adherence. MethOds: Prescription drug data 
from a national retail pharmacy chain were used to identify new episodes of HIV 
therapy initiated between January 1, 2008 and July 31, 2012. The mix of medications 
used as initial therapy was defined using a 4 days window following the fill date of 
the initial HIV prescription. All episodes were screened for 6 months of data with no 
prior HIV prescriptions and for one year of post data. Patient characteristics included 
age, gender, state of residence and health insurance type. Regimens were classified 
according to the United States (US) Department of Health and Human Services (DHHS) 
treatment guidelines. Adherence was measured as the proportion of days covered 
[PDC] and PDC≥ 90%. Results: 113,933 episodes met study criteria. Patients were 
predominately male and between ages 35 and 55. Average PDC was 41.4% and only 
16.2% of patients achieved PDC≥ 90%. Multivariate analyses found that adherence 
increased monotonically with age and with male gender. Nearly 43% of patients used 
a DHHS preferred regimen and achieved significantly better adherence. Patients were 
less adherent when ritonavir was added to the treatment regimen. Using the single 
tab DHHS preferred regimen increased the likelihood of achieving PDC≥ 90% [Odds 
ratio = 1.23; (1.16-1.30)]. Patients using non-DHHS guideline regimens were less likely 
to be adherent though their PDC increased monotonically with the number of drugs 
used. cOnclusiOns: The quality of HIV drug therapy in the US is mixed. While 59% 
of patients use a DHHS approved regimen, 30% of patients used only a single medi-
cation. Just over 16% of patients achieved a PDC of ≥ 90%. However, this goal is more 
likely to be achieved when prescribing follows treatment guidelines.
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Objectives: Elderly population has a higher chance of developing pneumococcal 
disease and is recommended to receive pneumococcal vaccination by government 
agencies around the world. In the U.S., CDC reports pneumococcal vaccination 
coverage in the elderly annually. However, the pneumococcal vaccination coverage 
in elderly outside of the U.S. is unclear. The objective of this study was to review 
published data on the current global pneumococcal vaccination. MethOds: A 
systematic literature review was conducted in PubMed/MEDLINE to identify stud-
ies published between 2011-2013 that have assessed pneumococcal vaccination 
coverage in elderly population aged 65 years or older. Results: Thirty-nine stud-
ies that assessed pneumococcal vaccination among elderly were identified, with 
16 from North America (NA), 11 from Western Europe (WE), 7 from Asia Pacific 
(AP), 3 from Latin America (LA), and 2 from the Middle East (ME). No studies were 
found in Eastern Europe (EE) and Africa. Around 70% of identified studies were 
from NA and WE, where most governments have recommended pneumococcal 
vaccines for elderly. While many countries in AP, LA, and EE have similar recom-
mendations, only a few countries have conducted studies to assess the vaccination 
coverage to explore the policy uptake. Limited countries in Africa and ME have 
national recommendations, which could be the reason why the related research 
has been scant. Overall, 15 studies explored pneumococcal vaccination for general 
older population, while the rest (n= 24) assessed coverage for elderly with certain 
conditions or sociodemographic characteristics, or in specific settings. Population-
based studies showed that the pneumococcal vaccination coverage in elderly 
ranged 49.8%-68.6% for NA (n= 5),36.4%-50.9% for WE (n= 2),18.4%-61.0% for AP 
(n= 5),8.7%-44.3% for LA (n= 2), and 72% for Israel (n= 1). cOnclusiOns: Limited 
data on pneumococcal vaccination in elderly were reported for countries in LA, AP, 
EE, ME, and Africa regions. Further studies that examine pneumococcal vaccina-
tion in these regions are needed to evaluate the implementation of related policy.
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EQ-5D Index and EQ-VAS; these are standardized, preference-based measures of 
health. Results were reported in descriptive and stratified analyses. Linear regres-
sion analyses were performed to determine the independent associations with 
the EQ-5D. Results: There were 297 matched physician and patient response 
forms. Mean patient age was 50 years and 64% were male. Mean EQ-5D Index was 
0.764 (SD= 0.283; range= -0.199-1.000). Mean EQ-VAS was 65.85 (SD= 21.00; 
range= 5-100). EQ-5D Index and EQ-VAS scores were significantly lower with wors-
ening disease severity. Among patients who had completed treatment, EQ-5D 
scores were higher for patients who achieved sustained virologic response (SVR) 
compared to those who did not (EQ-5D Index= 0.873 vs. 0.660, p-value= 0.0035). 
Regression models showed higher age and worsening disease severity were sig-
nificantly associated with lower EQ-5D Index and EQ-VAS scores. cOnclusiOns: 
In a cross-sectional sample of HCV patients in France, utilities are linearly and 
significantly associated with disease progression, SVR, and age. This informa-
tion will be used to understand the benefits of treating patients and preventing 
disease progression.
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Objectives: In 2012, the US Centers for Disease Control and Prevention published 
recommendations of one-time Hepatitis C virus (HCV) screening for adults born 
during 1945 through 1965. Evaluating U.S. HCV populations by birth segment may 
provide insights that could be increasingly relevant to payers and health care 
providers. MethOds: Unique respondent data from the U.S. National Health and 
Wellness Survey from 2009-2012 were analyzed. Individuals aged ≥ 18 years who 
self-reported a Hepatitis C diagnosis were stratified into 3 cohorts based on birth 
year: pre-1946, 1946-1964, and post-1964. Characteristics, treatment rates, QOL 
(SF-12/36), and activity impairment (WPAI) were described. Results: Individuals 
born between 1946-1964 represented 64.6% of respondents with Hepatitis C (13.0% 
were older; 22.3% younger). The 1946-1964 cohort had a higher proportion of males 
than the younger population (65.3% vs. 59.3%, respectively; p< 0.05); 64.2% pre-1946 
were male. Insured status was higher (p< 0.05) in the older cohort (96.5%) versus 
the 1946-1964 (75.5%) or younger (70.2%) cohort. Reported current HCV treatment 
use was lower (p< 0.05) in the older cohort (3.2%) versus 1946-1964 (10.7%) or post-
1964 (21.4%). More than half in each cohort were treatment naïve (64.2% pre-
1946; 53.5% 1946-1964; 53.4% post-1964). A lower (p< 0.05) proportion (10.3%) of 
treatment naïve respondents born pre-1946 had a prior doctor recommendation 
for HCV therapy (versus 21.0% 1946-1964 or 21.1% post-1964). Mean percentage 
activity impairment was lower (p< 0.05) among pre-1946 cohort (34.4%) versus 
1946-1964 (45.3%) or post-1964 (45.1%). Mean Mental Summary Scores worsened 
from oldest to youngest cohorts (pre-1946= 50.6; 1946-1964= 43.8; post-1964= 39.5). 
Mean Physical Summary Scores were higher for the younger cohort (43.6) versus 
1946-1964 (40.2) or pre-1946 (41.2). cOnclusiOns: In this Hepatitis C population 
analyzed by birth segment, individuals born 1946-1964 represented the largest 
segment of the population. Results suggest that differences by birth cohort may 
exist within this population regarding their characteristics, treatment rates, and 
patient-reported outcomes.
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Objectives: No standardized methods to measure outcomes related to commu-
nity-acquired bacterial pneumonia (CABP) have been developed since release of 
the FDA Patient Reported Outcome (PRO) Guidance. The purpose of this literature 
review was to identify signs, symptoms, and measurement tools associated with 
patient experience of CABP. The results will be used to inform the development of 
a standardized measurement tool for CABP that is consistent with the FDA PRO 
Guidance. MethOds: A search was conducted using OVID. MEDLINE (1946-present) 
and EMBASE (1988-2012) were searched using terms related to signs and symp-
toms of CABP and existing measurement and diagnostic tools. Results: The search 
identified 2158 abstracts. 940 were excluded based on pre-specified criteria. The 
remaining 1218 articles were scrutinized for eligibility resulting in 39 meeting the 
inclusion criteria. Thirty-four articles focusing on CABP signs and symptoms were 
identified in the literature. The most commonly reported symptoms were cough, 
chest pain, dyspnea, sputum production, and fatigue. The literature revealed that 
generic PRO instruments and an interviewer-administered measure including 10 
CABP symptoms have been used in CABP studies. Four CABP-specific instruments 
that assess patient-reported symptoms revealed notable methodological limitations 
and these were developed prior to the FDA PRO Guidance. cOnclusiOns: There is 
a paucity of evidence on the most well-defined, reliable, reproducible, and feasible 
method for measuring efficacy outcomes in CABP trials. Establishing an appropri-
ate PRO endpoint for CABP is essential. Existing CABP-specific instruments were 
identified, however, they have methodological limitations, and were all developed 
prior to the FDA PRO Guidance. There is a need to develop a new PRO instrument in 
accordance with FDA guidance for PRO measures. The instrument should address 
limitations of current tools and accurately capture data on concepts and outcomes 
most important to patients.
initiated STRs; 1,681 (47%) initiated MTRs. Median persistence (95% confidence 
interval) was 36.5 (31.3, 38.9) months on STRs and 13.2 (11.9, 15.0) months on MTRs 
(Difference 23.3; P< 0.001).Within the subgroups persistent for the first 6 months, 
median persistence on MTRs was 26.1 (24.2, 28.3) and on STRs was 47.6 (41.2, 
54.3) months. Limiting the MTR analysis to those patients who had persistence ≥ 
6 months still fell short of the overall STR persistence (P< 0.001). cOnclusiOns: 
Patients receiving an STR regimen had significantly longer median persistence, 
by almost two years, compared to those receiving MTRs. Even those patients who 
persisted on an MTR for the first 6 months experienced shorter overall persistence 
than those receiving an STR.
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Objectives: The aims of this study were to (1) Estimate the relative strength of 
preferences for different attributes of Anti Retroviral Therapy (ART) using a stated 
preference discrete choice experiment (DCE) and (2) incorporate findings from quali-
tative research to supplement the data from the DCE. MethOds: A European study 
in France, Italy, Spain, Germany and the UK was undertaken with an estimated1500 
PLWH designed to elicit patients’ strength of preference for different attributes 
of ARTs. This work presents the results from the UK and Germany. Participants 
were given a series of choice-style questions which presented hypothetical ARTs. 
Qualitative data were collected separately through individual interviews (n= 48) 
with PLWH recruited from HIV clinics in the UK and Germany. Results: In total, 
549 patients participated in the DCE (249 in UK) and (300 in Germany). The results 
showed that a rapid improvement in CD4 count and viral load were treatment attrib-
utes valued most highly by patients (UK: OR= 0.79; CI= 0.69-0.90; P< 0.001. Germany: 
OR= 0.79; CI= 0.71-0.87; P< 0.001). In addition, the absence of side effects such as diar-
rhoea was also valued highly (UK:OR= 0.57 CI= 0.51-0.65, p< 0.001. Germany: OR= 0.79, 
CI= 0.72-0.86; P< 0.001), as well as lower risk of long- term toxicities such as decline 
in renal function and an increase of cardiovascular risk (UK: OR= 0.30 CI= 0.25-
0.35, p< 0.001. Germany: OR= 0.55, CI= 0.48-0.63, p< 0.001). Other treatment attributes 
driving patient preference included reduction in treatment failure, absence of food 
restrictions with ART, and fewer drug-drug interactions (DDIs). The main differ-
ence between the German and UK results is that German patients did not value 
the absence of DDIs, the qualitative data suggests that they felt that these issues 
are being managed by their clinician. cOnclusiOns: The DCE demonstrated that 
patients placed a great deal of importance on treatment efficacy as evidenced by 
the importance placed on these attributes.
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Objectives: Health state utility values (HSUVs) in HIV are a key component of 
economic models that include Quality Adjusted Life years (QALY). There are limited 
HSUVs previously reported in HIV patients from Kenya. The objective of this study 
was to examine the HSUVs by severity of symptoms in an HIV infected popula-
tion. MethOds: A Kiswahili translated SF-12 survey was administered to newly 
diagnosed HIV infected patients participating in a randomized, controlled trial in 
Nairobi, Kenya between April and October 2013. Patients were also asked if they were 
experiencing common symptoms of HIV (ie. fatigue, loss of appetite, depression or 
diarrhea) on a scale including no symptoms, mild, moderate or severe symptoms. 
SF-12 results were scored using Brazier’s SF6D utility algorithm. Mean HSUVs among 
patients reporting severe symptoms, mild/moderate symptoms or no symptoms 
were compared using ANOVA. Results: 135 respondents were included in the anal-
ysis with 7 observations removed due to missing data. HSUvs among asymptomatic 
HIV patients was 0.98 (SD= 0.04), among patients experiencing mild/moderate symp-
toms was 0.89 (SD= 0.12) and among patients experiencing severe symptoms was 
0.73 (SD= 0.16). ANOVA showed significant differences (p< 0.01) between group and 
a post-hoc Tukey test confirmed mean HSUVs were significantly different between 
those reporting severe symptoms and the other categories. cOnclusiOns: This 
study measures HSUVs in a Kenyan cohort of HIV patients and confirms that sig-
nificant differences exist in quality of life between subgroups of these HIV infected 
patients. The utilities are inline with values measured in studies from other set-
tings. These HSUVs may be used to determine QALYs for use in health economic 
HIV research in Kenya.
PIN82
uTIlITy Values oF hePaTITIs c PaTIeNTs IN FraNce: resulTs by lIVer 
dIsease sTage aNd TreaTmeNT ouTcome
Samp J.C.1, Perry R.2, Piercy J.2, Baran R.W.1
1AbbVie, North Chicago, IL, USA, 2Adelphi, Macclesfield, UK
Objectives: France has a high prevalence of chronic hepatitis C (HCV) and clinical 
impacts of the disease are well recognized. Despite this, information on utility 
and health-related quality of life (HRQoL) is limited. While it is generally accepted 
that HCV patients have reduced HRQoL, delineation of these values by disease 
stage and treatment outcome is not clear. These differences are important for 
determining the benefits of treating patients and preventing disease progression. 
This study assessed utility values of HCV patients in France by disease stage and 
treatment outcome. MethOds: Physicians treating HCV patients in France were 
recruited to participate in the Hepatitis C Disease Specific Programme®. From 
October 2012 thru January 2013, physicians completed Patient Record Forms for 
10 consecutive patients presenting to their clinic. Information included patient 
demographics, disease stage, and treatment outcome. Patients completed the 
